On August 15, 2024, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi®) with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery, for adults with resectable (tumors that are 4 cm or larger or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) variants or anaplastic lymphoma kinase (ALK) rearrangements.
![FDA update](/sites/default/files/2020-05/FDA-Update-700_11_6.jpg)
Efficacy was evaluated in AEGEAN (NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial involving 802 patients with previously untreated and resectable squamous or nonsquamous NSCLC (stage IIA–IIIB, per AJCC 8th edition). Patients were randomized 1:1 to receive either durvalumab or placebo with platinum-based chemotherapy every three weeks for up to four cycles (neoadjuvant treatment), followed by either continued single-agent durvalumab or placebo every four weeks for up to 12 cycles (adjuvant treatment).
The major efficacy outcome measures were event-free survival (EFS), as assessed by blinded independent central review, and pathologic complete response (pCR), as assessed by blinded central pathology review. Median EFS was not reached (95% CI = 31.9, not estimable [NE]) in the durvalumab arm and 25.9 months (95% CI = 18.9, NE) in the placebo arm (HR = 0.68; 95% CI = 0.53, 0.88; p = 0.0039). The pCR rate was 17% (95% CI = 13, 21) and 4.3% (95% CI = 2.5, 7) in the durvalumab and placebo arms, respectively. At the time of the prespecified interim analyses, overall survival (OS) was not formally tested for statistical significance; however, a descriptive analysis revealed no clear detriment.
The most common adverse reactions reported in at least 20% of patients in the clinical trial were anemia, nausea, constipation, fatigue, musculoskeletal pain, and rash. Of the patients who received neoadjuvant durvalumab, 1.7% were unable to receive surgery because of adverse reactions compared with 1% in the placebo arm.
For patients with a body weight of at least 30 kg, the recommended durvalumab dosage is 1,500 mg every three weeks (neoadjuvant treatment) or every four weeks (adjuvant treatment). For patients with a body weight less than 30 kg, the recommended durvalumab dosage is 20 mg/kg. Administer durvalumab prior to chemotherapy when both are given on the same day. View the full prescribing information for durvalumab at Drugs@FDA.
The applicant used the Assessment Aid to facilitate the FDA’s review.
Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 800-FDA-1088.
For assistance with single-patient applications for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov.